TWI882020B - 用於靶向病原性血管之化合物及方法 - Google Patents

用於靶向病原性血管之化合物及方法 Download PDF

Info

Publication number
TWI882020B
TWI882020B TW109136021A TW109136021A TWI882020B TW I882020 B TWI882020 B TW I882020B TW 109136021 A TW109136021 A TW 109136021A TW 109136021 A TW109136021 A TW 109136021A TW I882020 B TWI882020 B TW I882020B
Authority
TW
Taiwan
Prior art keywords
group
alkyl
optionally substituted
sulfonyl
ethylene glycol
Prior art date
Application number
TW109136021A
Other languages
English (en)
Chinese (zh)
Other versions
TW202128161A (zh
Inventor
孫暉
孫璞
程果
區祺俊
仲明
Original Assignee
美國加利福尼亞大學董事會
美商亞騰勁公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美國加利福尼亞大學董事會, 美商亞騰勁公司 filed Critical 美國加利福尼亞大學董事會
Publication of TW202128161A publication Critical patent/TW202128161A/zh
Application granted granted Critical
Publication of TWI882020B publication Critical patent/TWI882020B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
TW109136021A 2019-10-18 2020-10-16 用於靶向病原性血管之化合物及方法 TWI882020B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962916983P 2019-10-18 2019-10-18
US62/916,983 2019-10-18

Publications (2)

Publication Number Publication Date
TW202128161A TW202128161A (zh) 2021-08-01
TWI882020B true TWI882020B (zh) 2025-05-01

Family

ID=73198494

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109136021A TWI882020B (zh) 2019-10-18 2020-10-16 用於靶向病原性血管之化合物及方法

Country Status (9)

Country Link
US (2) US11884647B2 (enExample)
EP (1) EP4045485A1 (enExample)
JP (1) JP2022552019A (enExample)
KR (1) KR20220087497A (enExample)
CN (1) CN114793434A (enExample)
AU (1) AU2020365108A1 (enExample)
CA (1) CA3158150A1 (enExample)
TW (1) TWI882020B (enExample)
WO (1) WO2021076886A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12590298B2 (en) 2019-10-18 2026-03-31 The Regents Of The University Of California Ex vivo tumor angiogenesis model
EP4045485A1 (en) 2019-10-18 2022-08-24 The Regents Of The University Of California 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders
JP2025520186A (ja) 2022-07-15 2025-07-01 エルジー エナジー ソリューション リミテッド バッテリーパック、該バッテリーパックを含む自動車

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007072093A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. Quinoline derivatives useful in the treatment of mglur5 receptor-mediated disorders
WO2009019708A2 (en) * 2007-08-09 2009-02-12 Urifer Ltd Pharmaceutical compositions and methods for the treatment of cancer

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
JPH02262627A (ja) 1988-12-08 1990-10-25 Japan Synthetic Rubber Co Ltd 有機非線形光学素子
DE4014171A1 (de) 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
JPH0539272A (ja) 1991-01-09 1993-02-19 Nissan Chem Ind Ltd ピリミジンジオン誘導体および除草剤
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
DE4126244A1 (de) 1991-08-08 1993-02-11 Bayer Ag Massefaerben von kunststoffen
GB9221383D0 (en) 1992-10-12 1992-11-25 Minnesota Mining & Mfg Photothermographic imaging materials and antifoggants therefor
US5374514A (en) 1993-01-06 1994-12-20 Kirk; Mark P. Photothermographic materials
DK122693D0 (da) 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
AUPM425294A0 (en) 1994-03-04 1994-03-31 Australian National University, The In-vitro angiogenesis assay
JPH08157461A (ja) 1994-12-07 1996-06-18 Sankyo Co Ltd スルホン誘導体
US5576338A (en) 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
BR9711816A (pt) 1996-08-01 1999-08-31 Du Pont Composto, composição fungicida, método para controlar doenças de plantas causadas pelos agentes patogênicos f·ngicos de plantas, composição artropodicida e método para controlar artrópodes.
DE19638484A1 (de) 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
DE19638486A1 (de) 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
ZA986594B (en) 1997-07-25 1999-01-27 Abbott Lab Urokinase inhibitors
US6258822B1 (en) 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
US6504031B1 (en) 1998-08-06 2003-01-07 Milan Bruncko Naphthamidine urokinase inhibitors
US6284796B1 (en) 1998-08-06 2001-09-04 Abbott Laboratories Ukokinase inhibitors
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9822450D0 (en) 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
GB9822440D0 (en) 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
US6927214B1 (en) 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
CA2379819A1 (en) 1999-07-29 2001-02-08 Dana-Farber Cancer Institute, Inc. Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo
US6893812B2 (en) 2000-05-30 2005-05-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Three-dimensional ex vivo angiogenesis system
US6803369B1 (en) 2000-07-25 2004-10-12 Smithkline Beecham Corporation Compounds and methods for the treatment of neoplastic disease
NZ523749A (en) 2000-07-26 2005-03-24 Smithkline Beecham P Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
EP1719770A3 (en) 2000-09-21 2008-03-05 Smithkline Beecham Plc Quinoline derivatives as antibacterials
CN1545557A (zh) 2000-11-17 2004-11-10 �ݰ�Ī�﹫˾ 应用5,10,15,20-四(羧苯基)卟吩检测细胞及组织样本中癌前期状态的组合物和方法
GB0031086D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
US20050261298A1 (en) 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US20060111368A1 (en) 2002-06-26 2006-05-25 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
ES2340484T3 (es) 2002-11-05 2010-06-04 Glaxo Group Limited Agentes antibacterianos.
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
CA2539707C (en) 2003-09-23 2011-08-09 Merck & Co., Inc. Quinoline potassium channel inhibitors
JP2005126549A (ja) 2003-10-23 2005-05-19 Konica Minolta Medical & Graphic Inc 開始剤、組成物、ラジカル発生方法、平版印刷版作製用感光材料および平版印刷版の作製方法
PE20050676A1 (es) 2003-12-12 2005-11-02 Wyeth Corp Quinolinas referidas a enfermedades cardiovasculares
EP1773831A1 (en) 2004-07-08 2007-04-18 Glaxo Group Limited Antibacterial agents
EP1773847A2 (en) 2004-07-09 2007-04-18 Glaxo Group Limited Antibacterial agents
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
WO2006008644A1 (en) 2004-07-13 2006-01-26 Pfizer Products Inc. Antidiabetic compounds
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
WO2006040522A1 (en) 2004-10-12 2006-04-20 Astrazeneca Ab Quinoline derivatives
JP2008528588A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
WO2006081264A1 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
SG161217A1 (en) 2005-04-01 2010-05-27 Insa Rouen New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
US7732613B2 (en) 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
EP1994028A1 (en) 2006-03-02 2008-11-26 AstraZeneca AB Quinoline derivatives for treating cancer
WO2007099323A2 (en) 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
CA2643863A1 (en) 2006-04-07 2007-10-18 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2007138112A2 (en) 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2008010061A2 (en) 2006-07-17 2008-01-24 Glenmark Pharmaceuticals S.A. 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
AU2007325872B2 (en) 2006-11-08 2012-12-13 Macrogenics West, Inc. TES7 and antibodies that bind thereto
EP2081890B1 (en) 2006-11-09 2011-01-12 F. Hoffmann-La Roche AG Arylsulfonyl pyrrolidines as 5-ht6 inhibitors
TWI373467B (en) 2007-01-11 2012-10-01 Academia Sinica New aniline or phenol mustrads linked to dna-affinic molecules or water-soluble aromatic rings and their use as cancer
WO2009008906A2 (en) 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
GB0704906D0 (en) 2007-03-14 2007-04-25 Syngenta Participations Ag Fungicides
EP2147310A4 (en) 2007-04-27 2010-09-08 Univ Rochester COMPOSITIONS AND METHODS OF INHIBITING G-PROTEIN SIGNALING
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8063220B2 (en) 2007-06-22 2011-11-22 Richter Gedeon Nyrt. Sulfonyl-quinoline derivatives
US8679836B2 (en) 2007-10-01 2014-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of monitoring angiogenesis and metastasis in three dimensional co-cultures
WO2009082942A1 (en) 2007-12-19 2009-07-09 Ningbo Institute Of Materials Technology And Engineering, Chinese Academy Of Sciences Polythioetherimides and method for producing thereof
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
DE102008010661A1 (de) 2008-02-22 2009-09-03 Dr. Felix Jäger und Dr. Stefan Drinkuth Laborgemeinschaft OHG Verfahren zur Herstellung von Pyridin-2-Boronsäure und Derivaten davon
JP5371118B2 (ja) 2008-04-30 2013-12-18 興和株式会社 キノリン化合物
JP5551689B2 (ja) * 2008-06-17 2014-07-16 アストラゼネカ アクチボラグ ピリジン化合物
WO2011022216A1 (en) 2009-08-17 2011-02-24 High Point Pharmaceuticals, Llc Substituted pyridine derivatives, pharmaceutical compositions, and methods of use to treat oxidative stress
RU2595718C2 (ru) 2009-09-09 2016-08-27 Селджен Авиломикс Рисерч,Инк. Ингибиторы pi3-киназы и их применение
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
CN102844304B (zh) 2010-01-04 2014-12-31 日本曹达株式会社 含氮杂环化合物以及农园艺用杀菌剂
US20130274215A1 (en) 2010-04-08 2013-10-17 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis
TWI516264B (zh) 2010-05-06 2016-01-11 臺北醫學大學 芳香醯喹啉化合物
JP5784110B2 (ja) 2010-05-11 2015-09-24 サノフイ 置換されたｎ−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用
US8883978B2 (en) 2010-05-11 2014-11-11 Institute For Cancer Research Antibodies to tumor endothelial marker 7R
WO2011156557A2 (en) 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor
KR101195112B1 (ko) 2010-06-14 2012-10-29 인하대학교 산학협력단 암혈관내피세포의 분리방법 및 배양방법
EP2401915A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402338A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
WO2012003283A1 (en) 2010-06-30 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
EP2588473A1 (en) 2010-06-30 2013-05-08 Amgen Inc. Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
CN106107406B (zh) 2010-08-12 2020-06-09 弗门尼舍公司 提高甜味增强剂的稳定性的方法和包含稳定的甜味增强剂的组合物
RU2443697C1 (ru) 2010-12-21 2012-02-27 Александр Васильевич Иващенко Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
CA2826773C (en) 2011-02-24 2019-07-16 Emory University Jab1 blocking compositions for ossification and methods related thereto
AU2012265220A1 (en) 2011-05-31 2014-01-16 Merck Patent Gmbh Electrolyte formulations
WO2013020909A1 (en) 2011-08-05 2013-02-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Materials and methods for the treatment of tauopathies
ES2604958T3 (es) 2011-10-28 2017-03-10 Vanderbilt University Análogos de 2-(4-heterociclilbencil)isoindolin-1-ona sustituidos como moduladores alostéricos positivos del receptor muscarínico de acetilcolina M1
CN102516232A (zh) 2011-12-14 2012-06-27 无锡美克赛医药科技有限公司 一种ErbB2的小分子选择性抑制剂及其应用
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CN104583206A (zh) 2012-06-15 2015-04-29 加利福尼亚大学董事会 用于脑癌的新颖治疗剂
CN104812389B (zh) 2012-09-24 2020-07-17 润新生物公司 某些化学实体、组合物及方法
KR102000211B1 (ko) 2012-10-29 2019-09-30 삼성디스플레이 주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
US20160155575A1 (en) 2013-07-25 2016-06-02 Basf Se Methine dyes with large organic counter anion for dye sensitized solar cells
EP3097093A1 (en) 2014-01-24 2016-11-30 Cadila Healthcare Limited Novel heterobicyclic compounds as kappa opioid agonists
EP3116873B1 (en) 2014-03-14 2018-02-28 AbbVie Deutschland GmbH & Co. KG Hexahydrodiazepinoquinolines carrying a cyclic radical
EP2982667A1 (en) 2014-08-04 2016-02-10 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Competitive PPAR-gamma antagonists
WO2016032569A1 (en) 2014-08-29 2016-03-03 Celladon Corporation Quinolines and their use for treating endoplasmic reticulum stress-caused diseases
TWI745284B (zh) 2015-01-22 2021-11-11 南韓商艾瑞多斯公司 化合物、彼之製法、及含彼之著色劑
US11680207B2 (en) 2015-03-03 2023-06-20 The Trustees Of The University Of Pennsylvania Direct mapping of local director field of nematic liquid crystals at the nanoscale
JP2016162983A (ja) 2015-03-04 2016-09-05 ダイキン工業株式会社 エッチング処理用組成物及びエッチング処理方法
NZ739185A (en) 2015-07-30 2022-10-28 Calgent Biotechnology Co Ltd Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
AR106515A1 (es) 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
US10501549B2 (en) 2015-11-30 2019-12-10 Seoul National University R&Db Foundation Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
MX2021006804A (es) 2015-12-17 2023-01-13 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
JP6983661B2 (ja) 2015-12-24 2021-12-17 協和キリン株式会社 α、β不飽和アミド化合物
US10081668B2 (en) 2016-04-26 2018-09-25 Northwestern University Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection
JP2019530435A (ja) 2016-08-15 2019-10-24 オルガノボ インコーポレイテッド 薬物試験のための三次元バイオプリント腫瘍モデル
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018068357A1 (zh) 2016-10-13 2018-04-19 西华大学 一类新型sirt2蛋白抑制剂及其在制药中的用途
WO2018119039A1 (en) 2016-12-23 2018-06-28 Felicitex Therapeutics, Inc. Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases
TW201827422A (zh) 2017-01-13 2018-08-01 大陸商江蘇恆瑞醫藥股份有限公司 １，２，４－三嗪－３－胺類衍生物、其製備方法及其在醫藥上的應用
WO2018200592A1 (en) 2017-04-24 2018-11-01 Regents Of The University Of California Biosynthesis of bioorthogonal amino acids
US20200275656A1 (en) 2017-05-03 2020-09-03 Bayer Aktiengesellschaft Trisubstitutedsilylmethylphenoxyquinolines and analogues
WO2019037678A1 (zh) 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019173482A1 (en) 2018-03-06 2019-09-12 Sanford Burnham Prebys Medical Discovery Institute 4-aminoquinoline compounds for the treatment of angiogenesis
CN115175680A (zh) 2019-10-18 2022-10-11 加利福尼亚大学董事会 Plxdc激活剂及其用于治疗血管病症的用途
EP4045485A1 (en) 2019-10-18 2022-08-24 The Regents Of The University Of California 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders
US12590298B2 (en) 2019-10-18 2026-03-31 The Regents Of The University Of California Ex vivo tumor angiogenesis model
WO2021076903A1 (en) 2019-10-18 2021-04-22 The Regents Of The University Of California Compositions and methods for detecting plxdc1 and plxdc2 in human tissues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007072093A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. Quinoline derivatives useful in the treatment of mglur5 receptor-mediated disorders
WO2009019708A2 (en) * 2007-08-09 2009-02-12 Urifer Ltd Pharmaceutical compositions and methods for the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Deli Sun, et al. "Visible-light-induced multicomponent cascade cycloaddition involving N-propargyl aromatic amines, diaryliodonium salts and sulfur dioxide: rapid access to 3-arylsulfonylquinolines." Chem. Commun., 54, 2018, 1335-1338.
期刊 Liangliang Zhang, et al. "tert-Butyl Hydroperoxide Mediated Cascade Synthesis of 3-Arylsulfonylquinolines." Org. Lett. 18, 6, 2016, 1286–1289.;期刊 Deli Sun, et al. "Visible-light-induced multicomponent cascade cycloaddition involving N-propargyl aromatic amines, diaryliodonium salts and sulfur dioxide: rapid access to 3-arylsulfonylquinolines." Chem. Commun., 54, 2018, 1335-1338. *

Also Published As

Publication number Publication date
WO2021076886A1 (en) 2021-04-22
US11884647B2 (en) 2024-01-30
AU2020365108A1 (en) 2022-04-21
US20240270717A1 (en) 2024-08-15
CN114793434A (zh) 2022-07-26
KR20220087497A (ko) 2022-06-24
CA3158150A1 (en) 2021-04-22
TW202602856A (zh) 2026-01-16
US20210147385A1 (en) 2021-05-20
US12612385B2 (en) 2026-04-28
TW202128161A (zh) 2021-08-01
JP2022552019A (ja) 2022-12-14
EP4045485A1 (en) 2022-08-24

Similar Documents

Publication Publication Date Title
CN108884043B (zh) 取代的哌啶化合物及其用途
TWI720451B (zh) 作為lsd1抑制劑之環丙胺
JP2020023529A6 (ja) Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
US12612385B2 (en) Compounds and methods for targeting pathogenic blood vessels
CN104024251A (zh) 苯磺酰胺化合物及其作为治疗剂的用途
CA2889378A1 (en) Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
EP3215504A1 (en) Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2015151490A1 (ja) 新規な三環性キノン誘導体
AU2013326850B2 (en) Novel compounds, their preparation and their uses
TW201326160A (zh) 雜環化合物及彼之用途
CN113801073B (zh) 14-氯-β-榄香烯一氧化氮供体型衍生物及其制备和应用
CN109867647A (zh) 3-取代的羰基萘并[2,3-b]呋喃衍生物或其药学上可接受的盐
CN110577526B (zh) 溴域结构蛋白抑制剂的盐及其制备方法和应用
CN107635980A (zh) 用于治疗疾病的葡糖神经酰胺合酶抑制剂
CN107459476B (zh) 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途
TW202421129A (zh) 用作 cdk4 激酶抑制劑的化合物及其應用
TWI723480B (zh) 用作fgfr4抑制劑的稠環衍生物
JP7853957B2 (ja) ピラゾールボロン酸化合物、それを含有する医薬組成物、及びそれらの使用
CN107207476B (zh) 吲哚和氮杂吲哚衍生物及其用于神经退化性疾病中的用途
CN109265471B (zh) Fxr受体激动剂
TWI923384B (zh) 用於靶向病原性血管之化合物及方法
TW202003519A (zh) 雜環化合物及其用途
WO2025051211A1 (zh) 用作cdk4激酶抑制剂的化合物及其应用
WO1999061414A1 (en) Novel substituted guanidine derivatives and process for producing the same
TW202325305A (zh) ２－（芳基－２－基）嗎啉及其氘代衍生物、製備方法和應用